Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
My guesses are biochica, carboat, frustrated, or dew
Looks like they already met,,,,,, says june 10
http://www.theflyonthewall.com/permalinks/entry.php/NSM?symbol=PPHM
for what its worth and i hope its true...........posted on another board.
silverback719•45 minutes agoFlag*******AKA MD1225
4users liked this postsusers disliked this posts4
Reply
Company had 6 meetings with Big pharmas this weekend
.
frontline data tba within next 2 weeks , there will be NO loan, and partnership will be annouced by end of summer whomever that will be. Bidding is now going on this is also fact.
Liver cancer trial going well MOS exceeding sorenafib by 7 weeks is the word fromUTSW.
be patient longs.....
Sentiment: Strong Buy
what is your opinion on all the new hiring going on at pphm???
Come on pphm, release a partnership pr!!!!!
wish i felt the same way.......id be happy to end the day in the 1.70s
thats the thing there is still a few catalyst that could come about,,,,,,,,,,,,BTD, AA, 1st line nsclc results,july earnings, etc
Why Peregrine Pharmaceuticals Shares Popped
By Sean Williams | More Articles | Save For Later
June 3, 2013 | Comments (0)
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Peregrine Pharmaceuticals (NASDAQ: PPHM ) , a biopharmaceutical company developing monoclonal antibodies to treat cancer, jumped as much as 19% after the company reported final data on its mid-stage second-line non-small cell lung cancer drug, Bavituximab, at the annual American Society of Clinical Oncology meeting.
So what: According to Peregrine's presentation at ASCO, Bavituximab devliered a median overall survival of 11.7 months in combination with docetaxel compared to just 7.3 months for the control arm. Additional studies also demonstrated slight improvements in overall response rate -- 17.1% for Bavituximab and 11.3% for the control arm -- and a 0.3 month improvement in median progression-free survival over the placebo. The data also suggested that Bavituximab was well-tolerated with a similar adverse events profile to that of the control arm.
Now what: If you've been following Peregrine, you're probably well aware of what a roller coaster that its phase 2 trial was. First the data was a knockout success, then it wasn't to be relied upon, and now it's a success again! Peregrine recently had the Food and Drug Administration lend its approval to the company's late-stage trial strategy and will begin enrolling patients shortly. Given the uncertainty that unfolded during phase 2 trials, I considered this late-stage trial the make-or-break one for Peregrine. Personally, though, I'd suggest keeping your distance, as small-cap biotechs don't have the best track record in producing successes in late-stage cancer trials.
While you can certainly make huge gains in biotechs like Peregrine, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report, "3 Stocks That Will Help You Retire Rich," names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.
Craving more input? Start by adding Peregrine Pharmaceuticals to your free and personalized Watchlist so you can keep up on the latest news with the company.
Hey cp, whats L3 looking like for today??
Hey cp, whats L3 looking like for today??
Now all we jeed is 1stline results and a partner pr this week and were golden
Any stars on ur yahoo portfolio this
a.m.?????
Does all the new hiring that pphm has been doing support gong to ph3 alone or with a partner based on the job description s you are all seeing?????
Bp are looking at pphm and that is a fact and you will see soon
Just a hunch.....no experience in this, but to me it makes to much sense. Could have been part of the 'collaborative' effort on the fda's part. 1st line results if im not mistaken have been postponed 3 times, so im sure fda is in touch with pphm often.
I just think the whole timing of ph3 approval news coming out 2 weeks prior to asco is strange. If they wanted to knock the socks off of the people at asco then why not wait to announce results till then, which mahes me wonder if they have an even bigger announcement to be made, but who knows.
I disagree . Fda already knows the frontline results and im sure that was one of the major deciding factors that allowed bavi to advace to ph3. Firstline validated the 2nd line results. If firstline results were no good 2nd line wouldnt have gotten to ph3
Unless theyre gonna offer $100 per share id prefer a partnership over a buyout
Anyone want to predict what the buyout price could be????
that would be great news! i wouldnt complain
any idea how much they are selling it for? could be an idea of how much they are willing to pay to play.
if it was a non event pphm wouldnt be at asco. the fda isnt saying show us what you got, they already know what we got. they wouldnt approve a drug for ph3 solely just because its safe. taking a tick tack is safe but if it doesnt help treat nscl they wouldnt approve it for ph3.
Whats your take on level2 today?
These guys never stop.....now there sayin pphm is running out of money and rushed their drug through fda approval and the price drop today from $2 was caused investors realized it...http://www.fool.com/investing/general/2013/05/20/these-winners-couldnt-send-the-dow-to-another-reco.aspx
Peregrine even mentions the agency in the headline of the press release, highlighting that the company "has reached agreement with the FDA." If the agency agreed to allow Peregrine to run the trial, it must think the trial will work right? Sorry, it doesn't really work that way.
basically he is saying the trial wont work. why else would he bring up the fact that just because the fda approved a drug doesnt mean it actually will produce evidence of improving life other than it being safe.
he was stating this to say, "hey why are all you buying pphm stock, just because fda approved ph3 doesnt mean its going to workout".......this article was a bashing one either way your read it. everyone knows just because a drug goes to ph3 it might not get appoved, so why write an article about it???!!!
this article is no different than AF statements.
http://ih.advfn.com/p.php?pid=trades&symbol=PPHM weird ah trading.......548,545 shares bought at 1.9243 and 548545 shares bought @ 1.9225 and low price trades in between at ah........those 2 trades you think they were from earlier in the day and finally went through. price seems to high for ah purchases from what im seeing with all the other 1.80s trading
writer basically says bavi doesnt work but fda will approve for ph3. even if ph2 was about safety they wouldnt approve it for ph3 if it didnt work at some level to improve mos!!!!
Crap article . Very very funny to read, writer says drug basically doesnt work BUT fda will approve for ph3!!!!!!!http://www.fool.com/investing/general/2013/05/20/biotech-companies-the-fda-doesnt-care-about-your-p.aspx
Ph3 approved!!!!!!!!!!!!!!!!!!!!
No one cares
Im sure you were already very aware of this, nice try at geting the newbies to sell
im sure when it hit $70 back then the o/s wasnt that high, so it could have been a little easier to hit that back then than now.
so it seems as though manangement isnt an issue this week with you like last week was, oh what will it be next week.
Sk's main purpose is to cure cancer and not pad your pockets with money and address a basher. Get real chica..pphm needs to focus on the fda and not bashers. The money will come when fda is addressed and not a basher
institution that did buy and are buying, are they buying common stock or preferred stock?
What does all that mean???
It would appear so, for what purpose who knows
As of March 11, 2013, there were 137,110,758 shares of common stock, $0.001 par value, outstanding
http://yahoo.brand.edgar-online.com/displayfilinginfo.aspx?FilingID=9155137-1042-201705&type=sect&dcn=0001019687-13-000816
UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 FORM 10-Q ýQUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 31, 2013 OR oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______________ to _______________Commission file number: 0-17085PEREGRINE PHARMACEUTICALS, INC.(Exact name of Registrant as specified in its charter) Delaware 95-3698422(State or other jurisdiction of (I.R.S. Employerincorporation or organization) Identification No.) 14282 Franklin Avenue, Tustin, California 92780-7017 (Address of principal executive offices) (Zip Code) (714) 508-6000(Registrant’s telephone number, including area code) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.Yes ý No oIndicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).Yes ý No oIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one) Large Accelerated FileroAccelerated Filer ý Non- Accelerated FileroSmaller reporting companyo(Do not check if a smaller reporting company) Indicate by checkmark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Yes o No ý As of March 11, 2013, there were 137,110,758 shares of common stock, $0.001 par value, outstanding